Showing posts with label nucleotide. Show all posts
Showing posts with label nucleotide. Show all posts

Wednesday, April 20, 2016

Australia's Future in Global Peptide Drug Development


Paul Watt, Chief Scientific Officer, Phylogica Ltd, Australia sat down with the TIDES team to discuss the future of global peptide drug development in Australia as well as the current challenges for intracellular drug delivery and the important roles that academic institutions have in the development and commercialization of peptide therapeutics. Below you will find a brief excerpt from this exclusive interview. To access the complete interview, click here.


In terms of investment and innovation, where do you see Australia's future in global peptide drug development?

Australians have had a long history in peptide discovery. For example the pioneering work of Professor Mario Geysen enabled the parallel synthesis of peptides in the early 80's. More recently Australia has accumulated multiple high achieving peptide scientists such as Paul Alewood (eg. synthesis toxin peptides including use of selenolanthionine bridges), Richard Lewis and Glenn King (ion channel active venom peptides) (including ion channel inhibitors). David Craik (cyclotides and structural biology of complex peptides), John Wade (neuropeptides/relaxins). Australian peptide innovation has been successfully commercialised with the establishment of multiple companies, including Mimotopes, Auspep, Protagonist and Phylogica. As many of these companies mature, I see a bright future in the development of the Australian peptide industry. In addition several peptides discovered in Australia have been subject of multiple alliances with big Pharma offering further commercial potential as they progress through clinical development.


To learn more from Paul, join him at TIDES, May 9-12, 2016 in Long Beach, CA. Where he will be discussing how to design oligonucleotides with better drug-like properties to accelerate your products from discovery/preclinical to the clinic and to market.  

Register for TIDES now and save $100, use the code B16180BLOG100.


Share this article with your social network, just click below to share now!


Thursday, March 24, 2016

Accelerate Your Peptide from Discovery to Commercialization


Accelerate your peptide product from early discovery through late-stage development and commercialization by attending IBC's 18th Annual TIDES meeting, held May 9-12, 2016 in Long Beach, California.

TIDES offers two tracks dedicated for peptide scientists to learn about the latest strategies and technologies needed to overcome challenges in targeting, drug discovery and peptide design, process development, regulatory, scale-up manufacturing, investment landscape and more:

Keynote Speaker:
Richard DiMarchi, Standiford H. Cox Professor of Chemistry, Indiana University
Mixed-Incretin Receptor Biochemical Signaling at Multiple Receptors

Track 1: Peptide Chemistry, Manufacturing & Controls
Speaking Organizations Include: Lonza, Bachem, Teva, Novartis, Peptron

Track 2: Peptide Discovery, Preclinical and Clinical
Speaking Organizations Include: Corden, Galena, Neon, Celerion, Phylogica

Learn about the Therapeutic Landscape of Peptides in 2016 and Beyond:
Rodney Lax, Ph.D., Business Consultant, PolyPeptide Group
Redefining the Therapeutic Peptide Business in the 21st Century

Plus, TIDES offers the largest and most focused exhibit hall for the peptide industry, where you can access 70+ vendor booths, 40+ posters and evening cocktail networking receptions to help grow your business. You won't want to miss out on this rare opportunity to connect with 800+ like-minded researchers from across the world.

As a reader of our blog, you are eligible to save $300 when registering for TIDES - Simply use the code B16180BLOG100. Click here to register.  


Share this article with your social network, just click below to share now!


Tuesday, February 23, 2016

From Critical Quality Attribute Assessment to Specification and Characterization



"The reason for assessing the critical quality attributes is not only to fulfill an expectation, but also because it serves as a better understanding of the product under development"

IBC's 18th Annual TIDES is the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization. The TIDES team recently talked to Renata Varga, Ph.D., Scientist - Characterization, Analytical Sciences, Global Biological CMC, Teva Pharmaceutical for an exclusive interview that delves into the topics he plans to discuss at the upcoming Oligonucleotide and Peptide Therapeutics event in Long Beach, CA.

In this interview, Dr. Varga discusses;
  • The key regulatory challenges facing peptide developers
  • What regulators look for when establishing CQAs in genetics, and any variation between generics and novel therapeutics.
  • Peptide innovation in the next 5 years

From Critical Quality Attribute Assessment to Specification and Characterization
Characterization and comparability assessment of peptide based generic products is driven by critical quality attributes (CQAs). Standard CQAs are identified based on regulatory requirements. Additional CQAs are determined by understanding the molecule itself: sensitive amino acids or which are involved in receptor-binding or mechanism of activation, are identified and based on uncertainty and impact the criticality of that attribute is defined. All standard- and additional CQAs are included in the specification while potential CQAs are further characterized by orthogonal techniques.


Register for TIDES now and save $500 - to save, use the code B16180BLOG100


Share this article with your social network, just click below to share now!


Tuesday, February 16, 2016

Efficient Chemoenzymatic Peptide Synthesis (CEPS) in Water


"When peptides are ligated in water, the crude reaction mixture can immediately be loaded on the preparative HPLC column to purify the product" 

IBC's 18th Annual TIDES is the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization. The TIDES team recently talked to Timo Nuijens, Ph.D., Lead Scientist, EnzyPep BV, The Netherlands for an exclusive interview that delves into the topics he plans to discuss at the upcoming Oligonucleotide and Peptide Therapeutics event in Long Beach, CA.

Efficient Chemoenzymatic Peptide Synthesis (CEPS) in Water
We describe a novel, organic cosolvent-stable peptide ligase (peptiligase), which couples peptide fragments with exceptional efficiency in water. Because peptiligase does not need a particular recognition motif, this novel technology is traceless and very broadly applicable. Besides fragment condensation, the enzyme is able to efficiently catalyze head-to-tail cyclization of peptides to create macrocyclics. It has also been shown to couple peptide esters efficiently to proteins. Peptiligase could be a useful tool for the (industrial) synthesis of numerous (pharmaceutical) peptides and conjugates.

In this interview, Dr. Nuijens also discusses;
  • The importance of fragment condensation of peptides in water
  • What the future holds for the Netherlands in the global peptide drug development market
  • The factors to consider when determining the optimal synthesis strategy when screening an enzyme

Register for TIDES now and save $500 - To save, use the code B16180BLOG100


Share this article with your social network, just click below to share now!


Tuesday, February 2, 2016

Impurity Guidelines to Oligonucleotides | An Interview with Andrew Teasdale of AstraZeneca


In a recent interview with TIDES, Andrew Teasdale, AZ Impurities Advisory Group Chair, AstraZeneca, United Kingdom examines the scope and applicability of both new guidance (ICH Q3D and ICH M7) and existing guidance (ICH Q3A / Q3B) to Oligonucleotides, looking into practical challenges and how they might be addressed and the potential application of generic, platform risk assessment approaches.


When discussing the impurities that face oligonucleotide developers, Andrew said, "The most common impurities in oligonucleotides are still related substances (oligomeric impurities)". However, this still begs to question what does one need to consider when mitigating risk for these impurities? Access the complete interview now.


To learn more from Andrew about oligonucleotide impurities, join him at IBC's 18th Annual TIDES event this May in Long Beach, CA where he will be speaking in his session titled "Assessment of the Relationship of Impurity Guidelines to Oligonucleotides - Opportunities for Rationale Approaches to Management of Risk". Download the brochure to access the complete agenda and speaking faculty.



Register for TIDES now and save $500 - To activate your savings, use the code B16180BLOG100


Share this article with your social network, just click below to share now!